Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study assessing safety and efficacy of selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer

Next Previous
Trial Profile

Study assessing safety and efficacy of selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary) ; Selinexor (Primary)
  • Indications Sarcoma; Solid tumours; Triple negative breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 10 Apr 2023 New trial record
  • 04 Apr 2023 Results published in the Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top